Sawyer & Company’s United Therapeutics UTHR Stock Holding History

Sawyer & Company’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,324	Closed	-$410K	–	176
2020 Q1	$410K	Sell	4,324 -1,000	-19%	-$95K	0.33%	73
2019 Q4	$469K	Hold	5,324	–	–	0.3%	76
2019 Q3	$425K	Sell	5,324 -336	-6%	-$27.1K	0.3%	74
2019 Q2	$442K	Sell	5,660 -400	-7%	-$37.4K	0.3%	78
2019 Q1	$711K	Hold	6,060	–	–	0.47%	68
2018 Q4	$660K	Sell	6,060 -150	-2%	-$17.4K	0.48%	65
2018 Q3	$794K	Hold	6,210	–	–	0.48%	62
2018 Q2	$703K	Hold	6,210	–	–	0.46%	66
2018 Q1	$698K	Hold	6,210	–	–	0.47%	64
2017 Q4	$919K	Buy	+6,210	New	+$789K	0.6%	58

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sawyer & Company's UTHR Position: Q2 2020 in Review

Sawyer & Company sold out of United Therapeutics (UTHR) in Q2 2020, closing a stake of 4,324 shares — an estimated $410K sold.

Sawyer & Company first reported a position in UTHR in Q4 2017 and held it in 10 quarters. The position peaked at $919K in Q4 2017. 349 funds tracked by Wall St. Rank hold UTHR as of Q2 2020.

Sawyer & Company reported no remaining United Therapeutics position as of Q2 2020 after selling out during the quarter.
Sawyer & Company sold 4,324 United Therapeutics shares in Q2 2020, an estimated $410K.
Sawyer & Company first reported a position in United Therapeutics in Q4 2017 and held it in 10 quarters.
Sawyer & Company's United Therapeutics position peaked at $919K in Q4 2017.
349 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2020.

Based on Sawyer & Company's 13F filing for Q2 2020, filed 31 Jul 2020.